$26.14
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says
Overview
52-week range
$8.20
$28
90% of range
Avg surprise (last 2)
+2.1%
Avg reaction (last 1)
+7.9%
100% positive
Latest IV / EM
111%
EM ±17.3% · $26 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Sun May 31, 2026 | May 2026 | $-0.81 | — | — | — | — | financials |
| Sat Feb 28, 2026 | Feb 2026 | $-0.79 | — | — | — | — | financials |
| Thu Oct 9, 2025 | Aug/2025 | $-1.03 | $-0.84 | -22.6% | — | — | earnings |
| Wed Jul 9, 2025 | May/2025 | $-0.52 | $-0.71 | +26.8% | — | +7.9% | earnings |
| Sat May 31, 2025 | May 2025 | $-0.52 | — | — | — | — | financials |
| Fri Feb 28, 2025 | Feb 2025 | $-0.67 | — | — | — | — | financials |
| Sat Aug 31, 2024 | Aug 2024 | $-0.67 | — | — | — | — | financials |
| Fri May 31, 2024 | May 2024 | $-0.71 | — | — | — | — | financials |
| Thu Feb 29, 2024 | Feb 2024 | $-0.76 | — | — | — | — | financials |
| Thu Aug 31, 2023 | Aug 2023 | $-0.68 | — | — | — | — | financials |
| Wed May 31, 2023 | May 2023 | $-0.45 | — | — | — | — | financials |
| Tue Feb 28, 2023 | Feb 2023 | $-0.75 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $6M | — | $8M | $44M | $18M | — | $13M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-94M | $-92M | — | $-91M | $-48M | $-63M | — | $-55M |
| Net income | $-90M | $-87M | — | $-86M | $-43M | $-56M | — | $-49M |
| EPS (diluted) | $-0.81 | $-0.79 | — | $-1.03 | $-0.52 | $-0.67 | — | $-0.67 |
Balance sheet (quarterly)
| Metric | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $68M | $71M | $247M | $78M | $84M | $76M | $110M | $99M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $456M | $554M | $607M | $441M | $515M | $564M | $619M | $456M |
| Total assets | $536M | $636M | $688M | $522M | $592M | $615M | $669M | $514M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $133M | $155M | $149M | $150M | $144M | $134M | $142M | $137M |
| Total equity | $403M | $481M | $539M | $372M | $448M | $481M | $527M | $377M |